What an Interventionalist Needs to Know About INOCA

Daniel Tze Yee Ang, Colin Berry
1. University of Glasgow, Glasgow, UK; 2. Golden Jubilee National Hospital, Clydebank, UK

Abstract
Ischaemia with non-obstructed coronary artery disease (INOCA) remains a diagnostic and therapeutic challenge. An anatomical investigation-based approach to ischaemic heart disease fails to account for disorders of vasomotion. The main INOCA endotypes are microvascular angina, vasospastic angina, mixed (both) or non-cardiac symptoms. The interventional diagnostic procedure (IDP) enables differentiation between clinical endotypes, with linked stratified medical therapy leading to a reduced symptom burden and a better quality of life. Interventionists are therefore well placed to make a positive impact with more personalised care. Despite adjunctive tests of coronary function being supported by contemporary guidelines, IDP use in daily practice remains limited. More widespread adoption should be encouraged. This article reviews a stratified approach to INOCA, describes a streamlined approach to the IDP and highlights some practical and safety considerations.

Keywords
Ischaemia with no obstructive coronary artery disease, ischaemic heart disease, coronary, angina, coronary microvascular dysfunction, vasospastic angina, interventional diagnostic procedure

The classic cause of ischaemic heart disease is epicardial coronary atherosclerosis, but disorders of coronary vasomotion are being increasingly identified.1-4 Anatomical imaging with CT coronary angiography (CTCA) is the first-line test for patients with known or suspected angina and no prior history of coronary artery disease (CAD).5 Anatomical imaging is useful to clarify the presence and extent of coronary atherosclerosis, but does not evaluate microvascular function or coronary artery spasm. This presents a diagnostic gap for patients with ischaemia with non-obstructed coronary artery disease (INOCA).

The strengths of invasive angiography are its high sensitivity for revealing coronary atherosclerosis, providing haemodynamic measurements and the option of following on with percutaneous coronary intervention (PCI). Its limitations are, first, that its spatial resolution of approximately 0.3 mm is insensitive in visualising resistance arterioles that help to modulate myocardial blood flow.2 Second, angiography does not directly assess vascular function. Despite adjunctive tests of coronary function now being recommended (class IIa) by contemporary guidelines, its uptake in daily practice remains limited.4

Up to 50% of patients with known or suspected angina have INOCA.3 Of these, 80% are found to have microvascular and vasospastic angina when studied using specific tests.3,6,7 These conditions are associated with an impaired quality of life, as well as greater morbidity and health resource utilisation.8,9 Dismissing these patients would be doing them a disservice.

Interventional cardiologists are uniquely placed in the care pathway to offer gold-standard assessment of the coronary circulation via the interventional diagnostic procedure (IDP). While disorders of coronary function may coexist in patients with epicardial stenosis, diagnostic testing remains limited in the presence of obstructive CAD. This review focuses on the diagnosis of INOCA, describes a streamlined approach to the IDP, and highlights some practical and safety considerations.

Importance of Diagnosis
Illness perception tends to be more threatening in patients with diagnostic uncertainty, which in turn leads to disability and absence from work.10 A conclusive diagnosis can be therapeutic, encouraging compliance with medication and lifestyle interventions. The CorMicA study demonstrated that an IDP with linked stratified medical therapy improved symptom burden, quality of life, treatment satisfaction and illness perception at 6 and 12 months.11 Invasive coronary angiography could therefore be considered incomplete without assessment of coronary vascular function.

Alternative Approaches
Some clinicians propose that ex juvantibus criteria for the management of these patients could convey the same benefits without an IDP, by instituting a therapeutic trial of vasomotor-specific antianginals in all patients. The arguments for this approach include a shorter procedural duration and reduced upfront cost from diagnostic guidewires, adenosine and acetylcholine.
Stratified Medicine

Stratified medicine is the identification of key subgroups within a heterogeneous population of patients, each with differing disease mechanisms and/or responses to treatment. Mechanistically linked treatments should be prescribed based on clinical endotypes, as determined from results of the IDP. Unnecessary medication should be discontinued, reducing polypharmacy and its possible side effects. This concept aligns with precision medicine – offering the ‘right treatment for the right patient at the right time’.

Ultimately, many of these patients are significantly affected by their symptoms, such that they may be willing to undergo invasive angiography with its small risk of life-threatening complications. We owe it to them to inform them about the risks and benefits and offer opportunity for further assessment.

Defining INOCA by Clinical Endotypes

Physiological coronary vascular function reflects a balance between vascular tone, vasodilator reserve and resistance. Vascular function may vary between coronary artery territories. Disorders cause a relative supply-demand mismatch of blood flow relative to requirements, resulting in ischaemia.

INOCA is considered after obstructive epicardial disease has been excluded via standard angiography, with or without measurement of non-hyperaemic pressure ratios and/or fractional flow reserve (FFR). The main INOCA endotypes to consider are described below. The Coronary Vasomotor Disorders International Study Group (COVADIS) has published standardised definitions to aid clinical diagnosis (Table 1).

Microvascular Angina

Microvascular angina (MVA) may involve one or more distinct mechanisms. This concept has also been described in heart failure with preserved ejection fraction. MVA is caused by microcirculatory disorders that may be functional, structural or both. Functional disorders impair coronary arteriolar vasodilation or vasoconstriction. Structural disorders relate to inflammation, inward remodelling of the vascular wall or interstitial matrix and/or capillary rarefaction. Remodelled arterioles have also demonstrated hypersensitivity to vasoconstrictor stimuli.

Epicardial Vasospastic Angina

Focal epicardial spasm was first described by Prinzmetal et al. in 1959 as ‘variant angina’. The defining feature is hyper-reactivity to vasoconstrictor stimuli. This includes both spontaneous spasm and episodes during provocation testing. It may exhibit a circadian pattern and be precipitated by stress or hyperventilation. Vasospastic angina (VSA) is typically occurs at rest but may also be induced by exertion in a minority of people.

Mixed Microvascular and Vasospastic Angina

VSA may coexist with microvascular disorders and/or structural epicardial disease. There is evidence that patients with mixed MVA/VSA have worse overall quality of life.

Non-Cardiac Symptoms

When coronary arteries are unobstructed and coronary function results are normal, alternative aetiologies for symptoms should be considered.

Functional Coronary Angiography and the Interventional Diagnostic Procedure

Functional coronary angiography integrates anatomical imaging with functional tests. The IDP increases the diagnostic yield and differentiates power of invasive angiography among patients with unobstructed epicardial coronaries. The additional information provided reduces diagnostic uncertainty and related variations in treatment.

The assessment of INOCA comprises two main components: diagnostic, guidewire-based assessment comparing flow at rest versus during hyperaemia; and pharmacological provocation testing for epicardial and/or microvascular vasoconstriction.

There is some debate regarding which test should be performed first. The authors advocate performing guidewire/adenosine studies first because of the risk of profound vasoconstriction during provocation testing, which can in turn elevate sympathetic drive and disrupt resting haemodynamic
Physiology. This accepts the small risk of incomplete nitrate metabolism before vasoreactivity testing.

Current diagnostic guidewires use either a pressure/temperature sensor for thermodilution or a Doppler/pressure sensor. Thermodilution-based wires are safe and straightforward to use. However, the benefits of complete diagnostic assessment should be acknowledged, including the reduced need for repeat referrals in the future.

**General Considerations**

Patient comfort and safety are paramount. A radial approach is recommended as per contemporary guidelines. An anxiolytic sedative facilitates a favourable patient experience but may, theoretically, reduce the propensity for inducing coronary spasm during acetylcholine provocative testing. All vasoactive medication should be withheld >24 hours beforehand, including abstinence from caffeine. This reduces the risk of false-negative results during vasoreactivity testing. Calcium channel blockers and long-acting nitrates should be avoided in the radial cocktail. Short-acting nitrates such as glyceryl trinitrate (which has a half-life of ~2 minutes) are preferred. Rapidly metabolised nitrates minimise the risk of false-negative results during vasoreactivity testing.

Measuring left ventricular end-diastolic pressure is recommended as elevated pressures might suggest alternative explanations for symptoms (e.g. decompensated heart failure), which may themselves be associated with microvascular dysfunction.

**Diagnostic Guidewire Assessment**

Resting thermodilution indices should be obtained in all patients undergoing FFR studies. This allows the option of completing hyperaemic indices during a single adenosine infusion after the FFR result is acquired. A bolus of intracoronary short-acting nitrate at the start mitigates any confounding epicardial spasm at rest. The guiding catheter is flushed with normal saline to avoid pressure-damping from contrast or blood. Allow 30 seconds for resting conditions to return before performing pressure wire equalisation. Meticulous initial set-up reduces the risk of pressure wire signal drift downstream.

The choice of guiding catheter should be personalised, taking account of the patient’s stature. A 6 Fr or 5 Fr guiding catheter represents an ideal balance between size, support and patient tolerability. ‘Balloon tracking’ or, alternatively, a ‘mother-and-child’ technique of advancing a 5 Fr diagnostic pigtail catheter inside a 6 Fr guiding catheter can help overcome issues with radial spasm and shearing injury during catheter advancement. The benefits of good catheter support are threefold: first, it reduces variation in the volume delivered from each saline bolus; second, less in-and-out recall of the catheter during rapid bolus injections reduces the risk of vessel injury; and third, reduced catheter movement sta bilises the diagnostic guidewire position within the vessel, thereby reducing variability in transit times.

Heparin (50–70 U/kg) should be administered to achieve an activated clotting time (ACT) of approximately 250 seconds before coronary perfusion.

**Summary of the IDP with practical considerations at each stage**

- **IDP step 1: diagnostic guidewire study + adenosine**
  - 6 Fr guide – ‘mother-and-child’ or ‘balloon tracking’ to facilitate catheter advancement if needed
  - Short-acting intracoronary nitrates to negate any epicardial spasm at rest
  - Flush guide and await return of resting conditions before equalisation
  - Diagnostic guidewire to distal third of target vessel (left anterior descending artery by default)
  - Standard coronary wire acting as ‘buddy wire’ can help advancement of diagnostic wire
  - Flush guide catheter before acquiring resting thermodilution transit times using a 3 ml syringe for saline boluses. Replace any outlier results for accurate CFR/IMR
  - Commence IV adenosine and repeat transit times after stable hyperaemia is confirmed

- **IDP step 2: vasoreactivity provocation testing**
  - Choice between infusion via standard guiding catheter versus dedicated microcatheter
  - Incremental acetylcholine challenge: infusions of 10⁻³, 10⁻⁴ and 10⁻⁵ at 1 ml/min for 2 mins. Finally, bolus of 100 μl over 20 secs
  - Monitor patient for change in vitals, heart rhythm and/or symptoms during infusions
  - Purge catheter after each infusion to avoid bolus of acetylcholine with next injection
  - Repeat angiogram after each infusion and compare to baseline. Assess for change in luminal diameter (>90% reduction = vasospastic angina) or drop in TIMI flow (microvascular spasm)
  - Bradycardia and heart block are usually self limiting, and can be mitigated with patient coughing manoeuvres. Chemical and electrical pacing are rarely necessary

**Figure 1: Interventional Diagnostic Procedure Workflow**

**3 ml bolus**

**10 ml saline**

**0.04” diagnostic wire**

**Diagnostic Guidewire Assessment**

- **Invasive coronary angiography + left ventricular end-diastolic pressure**
  - Radial approach
  - No vasoactive medication ≥24 h, including in radial cocktail
  - Short-acting nitrate (e.g. glyceryl trinitrate) preferred during procedure
  - Choose projections showing length of vessel without foreshortening or overlap
  - Exclude significant epicardial coronary stenosis

**Invasive coronary angiography + left ventricular end-diastolic pressure**

- **Radial approach**

**No vasoactive medication ≥24 h, including in radial cocktail**

**Short-acting nitrate (e.g. glyceryl trinitrate) preferred during procedure**

**Choose projections showing length of vessel without foreshortening or overlap**

**Exclude significant epicardial coronary stenosis**

**Invasive coronary angiography + left ventricular end-diastolic pressure**

- **Radial approach**

**No vasoactive medication ≥24 h, including in radial cocktail**

**Short-acting nitrate (e.g. glyceryl trinitrate) preferred during procedure**

**Choose projections showing length of vessel without foreshortening or overlap**

**Exclude significant epicardial coronary stenosis**
Coronary Flow Reserve

Coronary flow reserve (CFR) reflects the vasodilator capacity of the whole coronary circulation, including the epicardial coronaries and microcirculation. The WISE study demonstrated that low CFR was an independent predictor for the composite endpoint of death, non-fatal MI, non-fatal stroke or hospitalisation for heart failure (HR 1.20; 95% CI [1.05–1.38]; p=0.008).22

CFR can be impaired if basal coronary flow is high, diastolic time is reduced or intra-myocardial pressure is increased.3 Therefore, fluctuations in the resting haemodynamic status can lead to variability during repeat measurement. CFR is calculated from the principles of thermodilution by dividing the resting mean transit time by the hyperaemic mean transit time. A CFR of ≤2.0 is abnormal, with 2.1–2.5 reflecting a ‘grey-zone’ result.

Index of Microvascular Resistance

Coronary vascular resistance is mainly determined within the microcirculation. The apparent index of microvascular resistance (IMR) is the product of distal coronary pressure and hyperaemic mean transit time. An IMR if ≥25 is considered abnormal, with a few caveats: there is a weak correlation between IMR and subtended myocardial mass; and there is variation between ethnicities, with a lower cut-off suggested in Asians.24

Pharmacological Vasoreactivity Testing

Acetylcholine is now the default agent for provocation testing.25 Okumura et al. demonstrated that intracoronary acetylcholine had 90% sensitivity and 99% specificity for diagnosing epicardial spasm.26

Acetylcholine is an endogenous neurotransmitter acting on muscarinic and nicotinic receptors. In blood vessels, its effects reflect responses from both the endothelium and smooth muscle cells. Acetylcholine is not licensed for parenteral administration so gaining informed consent should take account of the rationale for its use. Acetylcholine testing assesses the physiological response, which, in a healthy artery, should be vasodilatation. In the presence of endothelial dysfunction, the response may be micro- or macrovascular spasm. The hospital pharmacy should facilitate drug access, storage, transport and reconstitution.

For the final stage of the IDP, intracoronary acetylcholine is infused via either the guiding catheter or a dedicated microcatheter. The benefit of a microcatheter is the theoretical avoidance of pan-coronary spasm. The CorMicA study demonstrated direct infusion using the guiding catheter was safe, and avoid the cost and risk of additional coronary instrumentation.5

Our protocol for acetylcholine provocative testing involves intracoronary infusion of incremental concentrations (10⁻⁶, 10⁻⁵, 10⁻⁴ mol/l) at 1 ml/min for 2 minutes using a mechanical pump, followed by a bolus of 100 µg (half dose for the dominant coronary artery) given over 20 seconds, with continuous monitoring of the ECG and patient.

An alternative approach is manual infusions of 2 µg, 20 µg, 100 µg and 200 µg. If infusing into a ‘dominant’ coronary artery, consider halving the dose to limit potential bradyarrhythmia. Before starting each infusion, first fill the guiding catheter lumen with infusate to reduce any ‘dead space’ effect when the infusion begins. Afterwards, ensure gentle purging of the catheter following each infusion to avoid a sudden bolus of acetylcholine with the next injection of contrast. Vigilance is required during infusions, with intracoronary nitrates at hand to reverse any spasm. The half-life of acetylcholine is <15 seconds, with effects ceasing rapidly once the infusion is stopped.27

Coronary angiography at a projection without vessel foreshortening is acquired at baseline, then repeated after each infusion. The vessel luminal diameter is compared to its size at baseline. A diameter reduction of >20% suggests endothelial dysfunction (MVA), while ≥90% reduction...
Endothelial dysfunction typically precedes atherosclerosis, Likewise, other studies demonstrated an incidence
Mechanism of Effect
Discontinue antianginal medication; consider continuing Treatment
Atropine 3
3
6,12
28
6
4
29
• Statins (e.g. atorvastatin 20–80 mg)
The monitoring for recommended Guideline-recommended
Guideline-recommended 3
43x62
set-up during invasive angiography facilitates safety. Vasospasm and of cardiac arrhythmias during provocation testing comparable with that risk in trained hands.
The CorMicA study demonstrated that the IDP is feasible, safe and low risk in trained hands. The monitoring set-up during invasive angiography facilitates safety. Vasospasm and bradycardia are usually transient. Patient coughing manoeuvres can help maintain haemodynamic perfusion in the event of asystole. Atropine and isoprenaline should be readily available, with electrical pacing rarely necessary.

Treatments
The goals of therapy are twofold: amelioration of symptoms; and reduction in cardiovascular risk. Linked stratified medical therapy guided by the IDP can improve angina and quality of life within a previously undifferentiated, heterogeneous population. Guideline-recommended treatments based on clinical endotype are summarised in Table 2. Bairey Merz et al. have published a review of current and upcoming treatments in INOCA. Endothelial dysfunction typically precedes atherosclerosis, which mandates aggressive treatment of cardiovascular risk factors.

Challenges in INOCA
INOCA testing, particularly the off-label use of acetylcholine, remains the remit of specific specialist centres at present, perpetuating limited experience in the wider community. Local arrangements are required for the supply of acetylcholine at each site, either as vials for reconstitution
INOCA for the Interventionalist
INTERVENTIONAL CARDIOLOGY: REVIEWS, RESEARCH, RESOURCES
Access at: www.ICRjournal.com

Table 2: Guideline-recommended Treatments Based on Clinical Endotype

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Treatment</th>
<th>Mechanism of Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microvascular angina</td>
<td>β-blockers (nebivolol 2.5–10 mg once daily)</td>
<td>↓ Myocardial oxygen consumption, Antioxidant properties</td>
</tr>
<tr>
<td>Calcium-channel blockers (amlodipine 10 mg once daily)</td>
<td>Vascular smooth muscle relaxation, ↓ Myocardial oxygen consumption</td>
<td></td>
</tr>
<tr>
<td>Nicorandil (10–20 mg twice daily)</td>
<td>Coronary microvascular dilator</td>
<td></td>
</tr>
<tr>
<td>Ranolazine (375–750 mg twice daily)</td>
<td>Improves microvascular perfusion reserve index in microvascular angina with reduced CFR</td>
<td></td>
</tr>
<tr>
<td>Trimeprazine (35 mg twice daily)</td>
<td>Increases cellular tolerance to ischaemia by maintaining homeostasis</td>
<td></td>
</tr>
<tr>
<td>ACE inhibitors (ramipril 2.5–10 mg once daily); angiotensin-receptor blockers if intolerant</td>
<td>Improves CFR, ↓ Workload, May improve small vessel remodelling</td>
<td></td>
</tr>
<tr>
<td>Calcium channel blockers (verapamil 240 mg once daily or diltiazem 120–360 mg daily)</td>
<td>Spontaneous and inductive epicardial coronary spasm via smooth muscle relaxation, ↓ Myocardial oxygen consumption</td>
<td></td>
</tr>
<tr>
<td>Nitrates (isosorbide mononitrate 20–120 mg daily)</td>
<td>↓ Spontaneous and inductive coronary spasm via epicardial vasodilatation, ↓ myocardial oxygen consumption</td>
<td></td>
</tr>
<tr>
<td>Nicorandil (10–20 mg twice daily)</td>
<td>Coronary vasodilator effect</td>
<td></td>
</tr>
<tr>
<td>Calcium channel blockers (amlodipine 10 mg once daily, diltiazem 90 mg twice daily or verapamil 240 mg once daily)</td>
<td>Vascular smooth muscle relaxation, ↓ Myocardial oxygen consumption</td>
<td></td>
</tr>
<tr>
<td>Mixed microvascular and vasospastic angina</td>
<td>Coronary microvascular dilator</td>
<td></td>
</tr>
<tr>
<td>Trimeprazine (35 mg twice daily)</td>
<td>Increases cellular tolerance to ischaemia by maintaining homeostasis</td>
<td></td>
</tr>
<tr>
<td>ACE inhibitors (ramipril 2.5–10 mg); angiotensin-receptor blockers if intolerant</td>
<td>Improves CFR, ↓ Workload, May improve small vessel remodelling</td>
<td></td>
</tr>
<tr>
<td>Non-cardiac symptoms</td>
<td>Discontinue antianginal medication; consider continuing cardiovascular risk reduction medication (e.g. statin) if coronary artery disease present</td>
<td>Cessation of unnecessary polypharmacy, Continue cardiovascular risk reduction, Consider referral to alternative specialty if appropriate</td>
</tr>
<tr>
<td>Cardiovascular risk reduction</td>
<td>Statins (e.g. atorvastatin 20–80 mg)</td>
<td>Improve coronary endothelial function, Reduced vascular inflammation</td>
</tr>
<tr>
<td>Antihypertensives</td>
<td>As per current hypertension guidelines</td>
<td></td>
</tr>
<tr>
<td>Lifestyle: smoking cessation, exercise, cardiac rehabilitation, Mediterranean diet, cognitive behavioural therapy</td>
<td>Improved exercise capacity and cardiac conditioning, weight reduction if overweight</td>
<td></td>
</tr>
</tbody>
</table>

Summary of European Association of Percutaneous Cardiovascular Interventions expert consensus and European Society of Cardiology chronic coronary syndromes 2019 guideline for recommended treatment based on clinical endotype. CFR = coronary flow reserve. Adapted from: Kunadian et al. 2020. Used with permission from Oxford University Press.

suggests VSA. Semiquantitative analysis of antegrade contrast flow may be undertaken by calculating the TIMI (thrombolysis in MI) frame count, with >27 (images acquired at 30 frames/second) suggesting MVA (coronary slow-flow phenomenon from microvascular spasm). A pressure wire pullback should be performed at the end of the IDP to exclude significant (>0.03) signal drift. The IDP can be repeated in different angiography, use of a guidewire and the physiological effects of acetylcholine including refractory coronary spasm, bradycardia and/or AF.

A pressure wire pullback should be performed at the end of the IDP to exclude significant (>0.03) signal drift. The IDP can be repeated in different coronary artery territories if false-negative results are suspected. Figure 2 highlights typical examples for each clinical endotype.

Risks and Safety Considerations
The main risks of the IDP are those relating to standard coronary angiography, use of a guidewire and the physiological effects of acetylcholine including refractory coronary spasm, bradycardia and/or AF. The CorMicA study demonstrated that the IDP is feasible, safe and low risk in trained hands. Likewise, other studies demonstrated an incidence of cardiac arrhythmias during provocation testing comparable with that observed during spontaneous spasm (6.8% versus 7.0%). The monitoring set-up during invasive angiography facilitates safety. Vasospasm and bradycardia are usually transient. Patient coughing manoeuvres can help maintain haemodynamic perfusion in the event of asystole. Atropine and isoprenaline should be readily available, with electrical pacing rarely necessary.
or as infusion-ready solutions from the pharmacy. The former option requires enhanced staff training, while the latter is more expensive. Patient reminders for abstinence of caffeine and vasoactive medication are needed during allocation of angiography appointments, to facilitate the option of vasoactivity testing on the day.

The management of INOCA often requires a period of optimisation; there is no one-size-fits-all panacea. Repeated clinical follow-up is necessary for individualised assessment and titration of medication to achieve the optimal patient-specific management plan.

Future Work
The true prevalence of INOCA in the general population remains unclear. Studies in cardiac catheterisation settings represent a highly selected and symptomatic subset, and fail to account for patients who are medically managed. While the CorMiCA pilot was successful in demonstrating the utility of the IPD, larger-scale, international studies are needed to strengthen practice guidelines. To this end, the iCorMiCA trial (NCT04674449) is currently recruiting.

Studies are under way for microvascular-specific therapies, including endothelin receptor antagonist zibotentan (PRIZE study; NCT04097314), coronary sinus reducer stent (NCT02710435), and pressure-controlled intermittent coronary sinus occlusion (NCT03625869).

Conclusion
INOCA remains a diagnostic and therapeutic challenge. There is growing evidence to support the use of adjunctive IPD in the assessment of INOCA, as reflected in the latest guidelines. Today’s interventionists are well placed to make a positive impact with more personalised care. The theoretical risk and added time of performing the IPD is outweighed by its benefits. More widespread adoption should be encouraged, as should its incorporation in training and professional standards.

**Future Work**
- The true prevalence of INOCA in the general population remains unclear. Studies in cardiac catheterisation settings represent a highly selected and symptomatic subset, and fail to account for patients who are medically managed. While the CorMiCA pilot was successful in demonstrating the utility of the IPD, larger-scale, international studies are needed to strengthen practice guidelines. To this end, the iCorMiCA trial (NCT04674449) is currently recruiting.

**Microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia. Results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) Study. J Am Coll Cardiol 2010;55:2525–32.**

**Conclusion**
INOCA remains a diagnostic and therapeutic challenge. There is growing evidence to support the use of adjunctive IPD in the assessment of INOCA, as reflected in the latest guidelines. Today’s interventionists are well placed to make a positive impact with more personalised care. The theoretical risk and added time of performing the IPD is outweighed by its benefits. More widespread adoption should be encouraged, as should its incorporation in training and professional standards.

**Future Work**
- The true prevalence of INOCA in the general population remains unclear. Studies in cardiac catheterisation settings represent a highly selected and symptomatic subset, and fail to account for patients who are medically managed. While the CorMiCA pilot was successful in demonstrating the utility of the IPD, larger-scale, international studies are needed to strengthen practice guidelines. To this end, the iCorMiCA trial (NCT04674449) is currently recruiting.

**Microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia. Results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) Study. J Am Coll Cardiol 2010;55:2525–32.**

**Conclusion**
INOCA remains a diagnostic and therapeutic challenge. There is growing evidence to support the use of adjunctive IPD in the assessment of INOCA, as reflected in the latest guidelines. Today’s interventionists are well placed to make a positive impact with more personalised care. The theoretical risk and added time of performing the IPD is outweighed by its benefits. More widespread adoption should be encouraged, as should its incorporation in training and professional standards.